I sent this here yesterday. Company values just this one program at 25m
Found something incredible interesting
‘As previously described in several filings with the Securities and Exchange Commission, ResolutionRx entered into a Letter of Intent (“LOI”) with Cantheon Capital (“Cantheon”) on May 18, 2023 that describes an intended investment of US$3,125,000 in Series A Preference Shares to be issued by ResolutionRx. According to the LOI, the issuance price was designated to be US$0.90 per Series A Share, which assumes 90% of a US$25 million maximum value’
Back in august 2023. When they established their Australian foot holding for their cannabinoid program the investment company they got with essentially validates Rspi judgment that their one program is worth 25m based on the issuance price.
Market Data 
Markets 
AI
